Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00009672 · ClinicalTrials.gov registry record · Phase 2

Pain Treatment for Sciatica

A Phase 2 study of Sciatica and Radiculopathy, sponsored by National Institute of Dental and Craniofacial Research (NIDCR).

Completed
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT00009672: Completed Phase 2 study of Sciatica and Radiculopathy, sponsored by National Institute of Dental and Craniofacial Research (NIDCR).

NCT00009672 is a Phase 2 study of Sciatica and Radiculopathy that has completed, run by National Institute of Dental and Craniofacial Research (NIDCR). The registered enrollment target is 80 participants, roughly in line with the 74-participant average among 6 other Sciatica trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00009672, a Phase 2 study of Sciatica and Radiculopathy, has completed, sponsored by National Institute of Dental and Craniofacial Research (NIDCR).

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This study will test the effectiveness of two drugs-nortriptyline and MS Contin (a type of morphine)-to treat pain caused by lumbar radiculopathy, or sciatica. Sciatica results from damage to the lumbar nerve roots, typically causing back pain and sharp, shooting pain down one or both legs. Although sciatica is common, there are no good treatments for it. Tricyclic antidepressants, such as nortriptyline, and opioids, such as morphine, have been effective in treating other kinds of pain from nerve damage. Patients between 18 and 65 years of age who have had sciatica pain daily for at least 3 months may be eligible for this study. Participants will provide a medical history and occupational and other social information. They will undergo a neurological examination, routine blood tests and an electrocardiogram and will fill out three questionnaires providing information on daily functioning and psychological well-being. This "cross-over" study consists of several parts, including a baseline study and four different treatment regimens. During each part, patients keep a daily log in which they rate their pain, record other procedures they undergo, such as injections and manipulations, and record medication side effects. In the first week of the study, patients remain on their current medications. Any antidepressants or opioids are stopped gradually before starting the drug trials. After the first week, patients go through the following four drug trials in random order: 1. Nortriptyline and inert placebo-Patients take nortriptyline in doses ranging from 25 mg. to 100 mg. and an inert placebo for morphine. (An inert placebo is a dummy pill; it looks like the test drug but has no active ingredient.) 2. MS Contin (morphine) and inert placebo-Patients take MS Contin in doses ranging from 30 mg. to 90 mg. and an inert placebo for nortriptyline. 3. Nortriptyline and MS Contin-Patients take MS Contin and nortriptyline in the same dose ranges as for each drug alone. 4. Activ

Conditions Studied

Interventions

  • DRUG Morphine
  • DRUG Nortriptyline

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2001-01-30
Est. Completion 2006-12-12
Phase Phase 2

What the finished NCT00009672 record still lists

NCT00009672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, roughly in line with the 74-participant average among 6 other Sciatica trials with a reported enrollment target.

The record links to 2 conditions, with Sciatica appearing as the primary indexed condition, and to 2 interventions - of which Morphine is the first listed.

NCT00009672 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00009672 about?

NCT00009672 is a clinical study titled "Pain Treatment for Sciatica". This study will test the effectiveness of two drugs-nortriptyline and MS Contin (a type of morphine)-to treat pain caused by lumbar radiculopathy, or sciatica. Sciatica results from damage to the lumbar nerve roots, typically causing back pain and sharp, shooting pain down one or both legs. Although...

What is the current status of trial NCT00009672?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2001-01-30. Estimated completion is 2006-12-12.

What conditions does trial NCT00009672 study?

This clinical trial studies the following conditions: Sciatica, Radiculopathy.

What interventions are being tested in trial NCT00009672?

The interventions under investigation include: Morphine (DRUG), Nortriptyline (DRUG).

Who is sponsoring clinical trial NCT00009672?

This trial is sponsored by National Institute of Dental and Craniofacial Research (NIDCR), which has 91 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00009672 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sciatica

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00009672, the US trial registry maintained by the National Library of Medicine. NCT00009672 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.